Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 5,530,000 shares, a growth of 8.0% from the December 15th total of 5,120,000 shares. Approximately 10.0% of the company's stock are short sold. Based on an average daily trading volume, of 831,700 shares, the short-interest ratio is currently 6.6 days.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,804 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares of the company's stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Inspire Investing LLC boosted its stake in Agios Pharmaceuticals by 34.2% during the 4th quarter. Inspire Investing LLC now owns 12,384 shares of the biopharmaceutical company's stock valued at $407,000 after purchasing an additional 3,156 shares during the period. Contravisory Investment Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $222,000. Nordea Investment Management AB lifted its stake in shares of Agios Pharmaceuticals by 3.6% in the 4th quarter. Nordea Investment Management AB now owns 220,569 shares of the biopharmaceutical company's stock worth $7,191,000 after acquiring an additional 7,593 shares during the period. Exome Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $2,941,000. Finally, Franklin Resources Inc. acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth approximately $1,499,000.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Royal Bank of Canada boosted their target price on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of "Hold" and an average price target of $56.33.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $0.60 during midday trading on Monday, hitting $32.42. The company's stock had a trading volume of 807,528 shares, compared to its average volume of 953,064. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58. The firm's fifty day moving average price is $44.72 and its 200-day moving average price is $45.10. The firm has a market cap of $1.85 billion, a P/E ratio of 2.85 and a beta of 0.87.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.